Clinical trials: Thyroid Eye Disease, TED

Thyroid Eye Disease

An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)

• Completed
• Age: 18 to 75 years
• Phase 3
• Results posted

This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, veligrotug (VRDN-001), in participants with chronic thyroid eye disease (TED).

Trial name

THRIVE-2 (NCT06021054)

Testing

Veligrotug

Where

57 sites in United States, Australia and 7 more

Volunteers

188 people

Sponsor

Viridian Therapeutics, Inc.